Linsitinib (OSI-906)

Catalog No.S1091

Linsitinib (OSI-906) Chemical Structure

Molecular Weight(MW): 421.49

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 270 In stock
USD 720 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Cancer Res 2013 73, 834-843. Linsitinib (OSI-906) purchased from Selleck.

    OSI-906 prevents the emergence and inhibits growth of established hormone-indendent tumors . A and B, MCF-7 cells were injected s.c. into athymic mice supplemented with 14-day release E2 pellets. Mice with no tumors (A) or bearing tumors ≥ 150 mm3 (B) were randomized to vehicle or OSI-906 (50 mg/kg/day, per os) for 6 weeks. Data are presented as number of tumors formed ; , P = 0.02, Fisher's exact test (A) , or mean tumor volume ± SEM; P < 0.05 versus vehicle, 2-way ANOVA (B). C, tumor-bearing mice from (A) were treated with vehicle or OSI-906 for 3 days. Xenografts were harvested 4 hours after the last dose. Tumor lysates were precipitated with a p-Tyr antibody; p-Tyr pull- downs and tumor lysates were analyzed by immunoblot with the indicated antibodies. D, tumor-bearing mice were imaged before and 4 hours after the initial dose of OSI- 906 by [18 F]FDG -PET. Images from a representative mouse show [18 F]FDG uptake pre- and post–OSI-906 (T-tumor ). Quantification is shown at the bottom.  , P < 0.0001, 2-way ANOVA .

    Cancer Res 2011 71, 6773-84. Linsitinib (OSI-906) purchased from Selleck.

  • (A) MHM cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) or Erlotinib (10 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. EGFR immuno-precipitates were probed with anti-phospho tyrosine antibody. In lanes marked “Serum Starved”, MHM cells were serum starved for 24 hours and stimulated with EGF (10 ng/ml) for 10 minutes. Lysates were collected and immunoblotted with indicated antibodies. (B) OS cell lines and primary OS cells were treated with CP (10 μM) alone, OSI-906 (5 μM) alone or with CP in combination with OSI-906 for 48 hours and whole cell lysates were immunoblotted with the indicated antibodies. (C) MHM and S4 (CP resistant MHM derivatives) cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. (D) IGF1 and IGF2 mRNA levels in untreated cells and cells treated with 10 μM CP for 48 hours were determined by qRT-PCR. The level of each mRNA transcript in untreated cells was considered “1.0” and all the other values were plotted relative to it. Shown are the mean results of three experiments, bars, Standard error (SE).

    Oncotarget, 2016, 7(19):27511-26. Linsitinib (OSI-906) purchased from Selleck.

     

    (A) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024, 1µM PPP or 1µM linsitinib for 24h and cell survival was determined by flow cytometry. Results are shown as mean  ± SEM, n=20. (B)CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024 (AG) or 1µM linsitinib (L) and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=6). (C) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1µM PPP and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=4). (D) CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with 5-15 µM AG1024 and subject to a Western blot analysis using the indicated antibodies. Results are represented as mean±SEM (n=10). Supplementary Figure 1C shows the associated densitometrical analysis after treatment with 15 µM AG1024. (E) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with 10-500nM rhIGF-1 and immunoblotted for the expression of IGF1R, pIGF1R, pAkt, Akt, pERK and Erk. A representative example from four independent experiments is shown.

    Linsitinib (OSI-906) purchased from Selleck.

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Targets
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
Abl [1]
(Cell-free assay)
ALK [1]
(Cell-free assay)
35 nM 75 nM 75 nM >10 μM >10 μM
In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk NYL0fY5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwMEK4NFYh|ryP M{\2VHNCVkeHUh?=
KS-1 NILzOI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfJOYNKSzVyPUCuNFM5OzVizszN MoDZV2FPT0WU
TE-11 M1j5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\6TWM2OD1yLkC3PFIzKM7:TR?= MX7TRW5ITVJ?
EW-1 M2L0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\DXHc{UUN3ME2wMlA5PTh3IN88US=> M4OxR3NCVkeHUh?=
HMV-II MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrEW2dTUUN3ME2wMlA5QDR4IN88US=> NVnuSVRpW0GQR1XS
COLO-205 MlztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTBwMUC0OVQh|ryP NVzi[lA5W0GQR1XS
ES1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHld|ExUUN3ME2wMlExPjl4IN88US=> MmPtV2FPT0WU
GDM-1 NFnteIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDpUYFKSzVyPUCuNVM3PzJizszN MnzmV2FPT0WU
ML-2 MkP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4m2XGlEPTB;MD6xOVg6PiEQvF2= NIjwNJJUSU6JRWK=
Saos-2 M1m5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojHTWM2OD1yLkG2OVI3KM7:TR?= NGfJOmNUSU6JRWK=
NCI-H1355 Mke4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rJRmlEPTB;MD6xPFE{PSEQvF2= NIXwSJhUSU6JRWK=
G-401 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwMUiyN{DPxE1? NWjtdHFnW0GQR1XS
EW-16 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PrNWlEPTB;MD6xPFc4PyEQvF2= M1fUPXNCVkeHUh?=
EW-7 MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjIUGJOUUN3ME2wMlE5QDhzIN88US=> MWLTRW5ITVJ?
NCI-H727 M133emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGW0N4FKSzVyPUCuNVk4QTRizszN M3qyOHNCVkeHUh?=
LCLC-97TM1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTBwMkC5OVUh|ryP M2T2bnNCVkeHUh?=
NCI-H650 M{TXWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PBZWlEPTB;MD6yNVM5PCEQvF2= M{DNS3NCVkeHUh?=
NCI-H2122 M2HSeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTrTWM2OD1yLkKzNlk6KM7:TR?= NVzoflh3W0GQR1XS
SK-N-DZ M1O1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1T2ZWlEPTB;MD6yN|Y6QCEQvF2= NUDTc4xWW0GQR1XS
HT-29 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwMkSyOFgh|ryP MnXWV2FPT0WU
LB771-HNC NF3CXHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLjTWM2OD1yLkK1PVE2KM7:TR?= NV[3XWxrW0GQR1XS
HT-144 MmrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwMk[xPVEh|ryP NUjPbnJ6W0GQR1XS
LAN-6 NEPIc29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHzTWM2OD1yLkK2N|Q5KM7:TR?= M{[wRnNCVkeHUh?=
EW-18 M1nB[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETreVZKSzVyPUCuNlcxODFizszN MnjDV2FPT0WU
LS-1034 MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7ZWplvUUN3ME2wMlI4OTN{IN88US=> NVLmOYVFW0GQR1XS
EW-11 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYG4SmliUUN3ME2wMlI5PDN{IN88US=> MUTTRW5ITVJ?
SNU-C1 NEGwTW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXruO|RwUUN3ME2wMlI6OzF|IN88US=> NXyzdnNTW0GQR1XS
RS4-11 NEfBb3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{e2Z2lEPTB;MD6zN|c2QCEQvF2= MnH0V2FPT0WU
ES4 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Pjc2lEPTB;MD60NVA{QCEQvF2= MXXTRW5ITVJ?
COLO-320-HSR NUO4eYF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\uTo5{UUN3ME2wMlQyOzZ6IN88US=> MUfTRW5ITVJ?
NB10 NF36N5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEj5UXNKSzVyPUCuOFU1OzdizszN M{XHTHNCVkeHUh?=
BFTC-905 MlT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjibmtZUUN3ME2wMlQ3PzV6IN88US=> NYj2SmlpW0GQR1XS
A375 NHOy[GdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrQV2RkUUN3ME2wMlQ4PjF5IN88US=> NXTGSVNLW0GQR1XS
SJRH30 Ml3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPScod{UUN3ME2wMlUxQDJ{IN88US=> MUTTRW5ITVJ?
NOS-1 NHq4XlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\rTGFKSzVyPUCuOVIzPjdizszN NEfaOJhUSU6JRWK=
SIG-M5 NH20RopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIn4V21KSzVyPUCuOVM2PTdizszN MWHTRW5ITVJ?
DOK NILoemRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTCOZBKSzVyPUCuOVU3KM7:TR?= NGPpU|ZUSU6JRWK=
NB69 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfrN5Q2UUN3ME2wMlU5OjV5IN88US=> M1G4bnNCVkeHUh?=
SK-NEP-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XYb2lEPTB;MD62NFI{PiEQvF2= Mlq3V2FPT0WU
SK-MM-2 M1vLTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvhTWM2OD1yLk[1OFkyKM7:TR?= MmX3V2FPT0WU
NCI-H358 M{TDfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1z4V2lEPTB;MD62O|A5OiEQvF2= NEfPRpRUSU6JRWK=
RH-1 M3Kwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwN{S4OVkh|ryP MlrmV2FPT0WU
NH-12 NUXxdHQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rSbWlEPTB;MD63OlA1PiEQvF2= MWTTRW5ITVJ?
TE-12 MnX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXH4N5R6UUN3ME2wMlc3PDh4IN88US=> M{LFXnNCVkeHUh?=
COLO-668 M3u1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjueFZKSzVyPUCuPFQ3PjZizszN M{npTXNCVkeHUh?=
PANC-08-13 NVXQb4dZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLJVVNKSzVyPUCuPFY{PzdizszN MX7TRW5ITVJ?
HCC2998 Mk\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:0eIxKUUN3ME2wMlg5OjZ|IN88US=> NF:2WWhUSU6JRWK=
ABC-1 NGTtSWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPLb21mUUN3ME2wMlkxOzV{IN88US=> MmTQV2FPT0WU
ES6 Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jGPWlEPTB;MD65NVA3PiEQvF2= NFOyc2pUSU6JRWK=
SNU-387 NH7DdmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\iTWM2OD1yLkm5N|k{KM7:TR?= Mn:wV2FPT0WU
CMK M3jV[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHnTWM2OD1yLkm5PVI6KM7:TR?= NHjNXnRUSU6JRWK=
SJSA-1 M4rEbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXT4UHZnUUN3ME2xMlA{PjV|IN88US=> NHHObFNUSU6JRWK=
SIMA MnLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mor6TWM2OD1zLkC2PFI2KM7:TR?= MULTRW5ITVJ?
ES3 M1;OUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTFwMUKyPVch|ryP MmDBV2FPT0WU
IGROV-1 M2LvZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHQcnkxUUN3ME2xMlE2PDR2IN88US=> M3n0O3NCVkeHUh?=
MEL-JUSO M3ixXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoD2TWM2OD1zLkG1O|U6KM7:TR?= MkfnV2FPT0WU
T84 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjkVIZKSzVyPUGuNlA6OTRizszN NF;pdXlUSU6JRWK=
CAL-85-1 M2T4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUm3PIVkUUN3ME2xMlI{OTN6IN88US=> M3zRZ3NCVkeHUh?=
RD NUTZdWp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHL1d5hKSzVyPUGuNlY1PTVizszN NYX5Z25NW0GQR1XS
TE-8 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\lWWJFUUN3ME2xMlMyPDZ{IN88US=> Mn[5V2FPT0WU
L-363 MljQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTFwM{SyNFgh|ryP M1HBfHNCVkeHUh?=
EKVX M4X5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEC3empKSzVyPUGuN|Q2PjhizszN NUjGcYZVW0GQR1XS
SK-MEL-3 NHLN[XJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnCTWM2OD1zLkS4OVU3KM7:TR?= MnHwV2FPT0WU
TGBC24TKB Ml3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTFwNUCxPVMh|ryP MoPZV2FPT0WU
NCI-H1770 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDCTWM2OD1zLkWxNVE{KM7:TR?= MYrTRW5ITVJ?
HuH-7 MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXO0TVg{UUN3ME2xMlYxODl6IN88US=> MYPTRW5ITVJ?
HL-60 NVrXS5V{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3yOmdiUUN3ME2xMlY3QTJ6IN88US=> MkHGV2FPT0WU
TE-1 Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXPTWM2OD1zLkewPVQ2KM7:TR?= NVfFWnBMW0GQR1XS
LC-2-ad MkW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHiTWM2OD1zLkezPFg4KM7:TR?= MX3TRW5ITVJ?
LB647-SCLC MnjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXLTWM2OD1zLke2OVg{KM7:TR?= M{HOXnNCVkeHUh?=
NCI-H2171 NFXUbnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXtTWM2OD1zLke3O|E3KM7:TR?= Mo\RV2FPT0WU
SK-PN-DW MlXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnTOoxEUUN3ME2xMlkyOjl6IN88US=> NETFNWdUSU6JRWK=
MC-IXC MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTFwOUi5PEDPxE1? MmT3V2FPT0WU
LS-513 MoLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofrTWM2OD1{LkC1N|A2KM7:TR?= M{DBNXNCVkeHUh?=
EW-3 NVzLS2ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\KTWM2OD1{LkC5PFQ1KM7:TR?= NVO2Z|N5W0GQR1XS
OPM-2 NX3ZU4lnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjGcXR3UUN3ME2yMlExOiEQvF2= NFO0eFRUSU6JRWK=
LP-1 M323SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LWUWlEPTB;Mj6yOVgxPyEQvF2= M1HGdHNCVkeHUh?=
LU-134-A MkH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTJwMke3JO69VQ>? MXvTRW5ITVJ?
CP66-MEL MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXRTWM2OD1{LkK5NFE1KM7:TR?= MXjTRW5ITVJ?
HCC1143 MmSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTJwNEWzOlgh|ryP M2HBenNCVkeHUh?=
LOXIMVI M{XjXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTJwNkCyNUDPxE1? NXTMPWRXW0GQR1XS
TE-10 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTJwN{C4N|gh|ryP NIiwPJFUSU6JRWK=
NCI-H1882 NXL6XYMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[5cmlEPTB;Mj63OVIzPyEQvF2= MnzWV2FPT0WU
CHP-126 MojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTJwN{[zNVch|ryP NWLBeIZDW0GQR1XS
NCI-H1623 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlS1TWM2OD1{LkmyNFI1KM7:TR?= MWXTRW5ITVJ?
GB-1 NEDWN4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTJwOUO0NFQh|ryP MljJV2FPT0WU
RCC10RGB MkLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvTOHRIUUN3ME2yMlk2OjhzIN88US=> MkLrV2FPT0WU
NCI-H2141 NF:4V4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvCVGZTUUN3ME2yMlk3QDl4IN88US=> NF\hNpZUSU6JRWK=
GI-ME-N NFjWSG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4q2VWlEPTB;Mz6wNFU3PSEQvF2= NGr3WXFUSU6JRWK=
NCI-H526 MkTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTNwMESwPFUh|ryP MnfOV2FPT0WU
NCI-H747 M1nzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEOxbnRKSzVyPUOuNFQ6QTJizszN M{LCUHNCVkeHUh?=
SNU-423 Mn7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTx[nE{UUN3ME2zMlIxOzF|IN88US=> MmK3V2FPT0WU
A427 NF\TbVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr3cW1KSzVyPUOuNlU3QTlizszN M4jFXHNCVkeHUh?=
CAL-12T MmDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4e4[GlEPTB;Mz60NFcyOyEQvF2= MmPCV2FPT0WU
LU-99A NVzDR25zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLOXXhKSzVyPUOuOFcyODVizszN MWXTRW5ITVJ?
MS-1 NFzIellIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTNwNUO0Nlkh|ryP NYfVZZZNW0GQR1XS
SK-LU-1 NVHYXG5[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjxZZFvUUN3ME2zMlc3Ojl3IN88US=> M1rvbXNCVkeHUh?=
SW837 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETqWmJKSzVyPUOuO|Y{OzNizszN NFPzd|FUSU6JRWK=
ES8 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XnbWlEPTB;Mz64N|g4PyEQvF2= NYjP[mpHW0GQR1XS
MZ2-MEL NFWz[phIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NImwN2JKSzVyPUOuPVIxQDZizszN NGXwTZVUSU6JRWK=
TGW NVfvOYY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTRwMEGzNVEh|ryP MlHRV2FPT0WU
GP5d NVLlVWZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3afY9EUUN3ME20MlA2OzZ{IN88US=> MnXQV2FPT0WU
BB49-HNC NWC3cWlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEK0c3lKSzVyPUSuNVUzOTNizszN MojEV2FPT0WU
NB13 MmLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfZRXhKSzVyPUSuNlY5QDdizszN MWrTRW5ITVJ?
NTERA-S-cl-D1 NHjNN5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTRwMki2NVUh|ryP NFvFc3JUSU6JRWK=
NCI-H1648 NVnDZZd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkj4TWM2OD12LkK5PFE6KM7:TR?= MV;TRW5ITVJ?
LCLC-103H M17CS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTRwM{KxPVUh|ryP M{X1fXNCVkeHUh?=
LS-411N M4LNU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmT0TWM2OD12LkS0PFg2KM7:TR?= NFixO4lUSU6JRWK=
NCI-H1092 MojIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnixTWM2OD12LkS1Olg4KM7:TR?= NX\DfoI4W0GQR1XS
PANC-10-05 NYfyOpd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rmN2lEPTB;ND62PVg1KM7:TR?= NUHLO|VnW0GQR1XS
DK-MG M2roWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTJTWM2OD12LkiwPVM{KM7:TR?= M3mwbHNCVkeHUh?=
OVCAR-5 MlTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnxTWM2OD12LkixNlI3KM7:TR?= NFTRbmFUSU6JRWK=
CAL-39 M33HPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\Pco5KSzVyPUSuPFc3PyEQvF2= NEXsXY5USU6JRWK=
TE-441-T NXfaWZkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGqwWoxKSzVyPUSuPVA2OzdizszN MYnTRW5ITVJ?
MOLT-16 MmOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYToXpdZUUN3ME20Mlk2OjV|IN88US=> NFrHZXZUSU6JRWK=
MCF7 NIjwVXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnzTWM2OD13LkG0OVE4KM7:TR?= Ml;HV2FPT0WU
CAPAN-1 NE\aXnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LoeWlEPTB;NT6yOVcxPyEQvF2= M17KWXNCVkeHUh?=
PSN1 NXzCd5p{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUf1OoR1UUN3ME21MlI4OjN3IN88US=> NG\4UphUSU6JRWK=
NCI-H292 M3;vbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;6eZNwUUN3ME21MlMxODR2IN88US=> M4rLSnNCVkeHUh?=
CPC-N MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEP4UpZKSzVyPUWuN|k1OTlizszN MlnkV2FPT0WU
DoTc2-4510 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LRRWlEPTB;NT60OVM4OSEQvF2= NXnwbY1yW0GQR1XS
LB1047-RCC M3e4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnPPZhKSzVyPUWuOVU6OzNizszN M1\0VHNCVkeHUh?=
MHH-ES-1 NHn6U45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HmZ2lEPTB;NT61PVkxPyEQvF2= M37Gb3NCVkeHUh?=
NMC-G1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTVwN{CyNlch|ryP MmriV2FPT0WU
SW1710 MmriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvQTWM2OD13Lke0O|UyKM7:TR?= NIjke2xUSU6JRWK=
YAPC MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jWS2lEPTB;NT63OlIxOSEQvF2= MUnTRW5ITVJ?
22RV1 NFHTdnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjXb4FHUUN3ME21MlgxODF7IN88US=> MYTTRW5ITVJ?
COLO-679 NFyxT|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXUTWM2OD13Lki4PVQ5KM7:TR?= NHLOUoVUSU6JRWK=
TCCSUP NIHBc4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLJUWpKSzVyPUWuPVMzPTlizszN NEPsRodUSU6JRWK=
C2BBe1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLqU|V{UUN3ME21Mlk{QTdizszN NFPxW2JUSU6JRWK=
TE-15 M{iw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTZwME[2NFUh|ryP NHzqWZVUSU6JRWK=
SCLC-21H NF3kfo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;BRXBKSzVyPU[uNVA5PDNizszN NYWzZo9[W0GQR1XS
EoL-1-cell M1rVOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTZwMU[1OlMh|ryP NUHodod2W0GQR1XS
NKM-1 NYrsTZkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXtZW9KSzVyPU[uNVY4OSEQvF2= MkL3V2FPT0WU
NCI-H1304 NHf1[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrMTWM2OD14LkK3OFI5KM7:TR?= M4SzUnNCVkeHUh?=
NB6 NUPMUm9QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmK4TWM2OD14LkK5OlIzKM7:TR?= M3O1XXNCVkeHUh?=
NALM-6 M4jyeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DaS2lEPTB;Nj6zN|I{KM7:TR?= MYLTRW5ITVJ?
NCI-H522 M4i4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nKZWlEPTB;Nj6zN|MxPiEQvF2= NHexT|FUSU6JRWK=
MV-4-11 NHfEfYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTZwM{ewO|kh|ryP NXjMNHd3W0GQR1XS
LB2241-RCC MlGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnxTWM2OD14LkO4OlY4KM7:TR?= MULTRW5ITVJ?
NCI-H1417 NF7OeXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTZwNEC4OFch|ryP NInWZ25USU6JRWK=
HT-1197 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\KTWM2OD14LkW3NVIzKM7:TR?= MmryV2FPT0WU
P30-OHK NFnmc|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDQ[JJNUUN3ME22MlYzPzdizszN MYLTRW5ITVJ?
ALL-PO MnLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGT6NGxKSzVyPU[uO|E6OTZizszN M2PmN3NCVkeHUh?=
OVCAR-4 NXvsVWx2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHNTWM2OD14Lke1OFA2KM7:TR?= M2fQUHNCVkeHUh?=
HCC2157 Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTZwN{e0O|Uh|ryP MVjTRW5ITVJ?
NCI-H838 NUDqNZlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvCTWM2OD14Lkm2OFkh|ryP MVzTRW5ITVJ?
NCI-H1299 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmD5TWM2OD14Lkm3NFkh|ryP MW\TRW5ITVJ?
SW954 M2S5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTdwMkCwOlgh|ryP M2nFbXNCVkeHUh?=
NCI-H441 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXoUlNKSzVyPUeuN|QxPjVizszN NH61U5lUSU6JRWK=
SK-MEL-2 NGnMT2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTdwNEizO|Mh|ryP NXm0OplIW0GQR1XS
KARPAS-45 MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDET|FKSzVyPUeuOlU6OjlizszN MoPXV2FPT0WU
CAL-54 NIi4V|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTdwOEK5O|ch|ryP NUPOV3BjW0GQR1XS
KYSE-180 NFXRN49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDUNZBkUUN3ME23Mlg5QTRzIN88US=> NELiW5NUSU6JRWK=
NCI-H187 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4f6VGlEPTB;Nz65OVk1PyEQvF2= NWDYVpMxW0GQR1XS
RT-112 NGDkfnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoCwTWM2OD16LkC5Olc4KM7:TR?= NGqwPZVUSU6JRWK=
NCI-H1437 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHyOnNKSzVyPUiuNFk4QTVizszN NF7UWJRUSU6JRWK=
SNU-449 MoW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRThwMkiyO|Ih|ryP NXHuOohDW0GQR1XS
HCC1187 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRThwMkmzPVEh|ryP NYDFSoRNW0GQR1XS
NCI-H2030 NXniNJk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETPNJBKSzVyPUiuN|c4OTRizszN M1z2UHNCVkeHUh?=
HuO-3N1 M2P0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljNTWM2OD16LkO3PFQ1KM7:TR?= NYf6S2toW0GQR1XS
COLO-792 NWO1R442T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRThwNEG1Nlch|ryP MV3TRW5ITVJ?
MIA-PaCa-2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjGO4NKSzVyPUiuPFU2ODhizszN NV\CWoJCW0GQR1XS
SK-N-FI NFf0SpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTlwMESyOUDPxE1? M3XHVHNCVkeHUh?=
MMAC-SF Mmn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGK4cYZKSzVyPUmuNFk4PTFizszN M3zZcnNCVkeHUh?=
NCI-H28 M3e1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4P2PWlEPTB;OT6xNFQ3QSEQvF2= M3rYfXNCVkeHUh?=
ETK-1 Mom2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\3TWM2OD17LkK5PVc1KM7:TR?= MUPTRW5ITVJ?
NCI-H1993 NHL2R5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XCSGlEPTB;OT60OFI3OSEQvF2= NGXQPJpUSU6JRWK=
no-11 M{DuSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HKV2lEPTB;OT60O|EzKM7:TR?= MWLTRW5ITVJ?
ChaGo-K-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoW3TWM2OD17LkWxOVg{KM7:TR?= M2nyfHNCVkeHUh?=
NCCIT NU\Ido4{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHq3O2xKSzVyPUmuOVMyPjlizszN MVrTRW5ITVJ?
SAS MkDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTFyLkK0PEDPxE1? NEOySYZUSU6JRWK=
A673 NFTZc5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrvb|RKSzVyPUGwMlM4ODRizszN M2PDd3NCVkeHUh?=
NCI-H1522 NGrYcotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDDWnhKSzVyPUGwMlM4ODdizszN MV3TRW5ITVJ?
NCI-H810 M13HXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nBTmlEPTB;MUCuN|kxPyEQvF2= MWDTRW5ITVJ?
IST-MES1 MkK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXyUFlKSzVyPUGwMlQ2PjRizszN MofSV2FPT0WU
GR-ST NETGXWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzGR4dHUUN3ME2xNE42ODJ2IN88US=> M4PiUnNCVkeHUh?=
SUP-T1 NGP5c2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;ufm9XUUN3ME2xNE44OzF5IN88US=> M2rBTnNCVkeHUh?=
NB5 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPzO|VKSzVyPUGwMlkxOjJizszN M1TxWnNCVkeHUh?=
MZ1-PC NWLDe2p[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoT5TWM2OD1zMD65OVcyKM7:TR?= NFz0N49USU6JRWK=
SK-CO-1 NViyWXM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHzXINKSzVyPUGwMlk6OzFizszN NULTZlk6W0GQR1XS
Capan-2 M{XKPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\JSIlKSzVyPUGxMlMyQThizszN Mn;qV2FPT0WU
697 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnmVZBKSzVyPUGxMlY4PTdizszN M{PkPHNCVkeHUh?=
REH M1G5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjReGVKSzVyPUGxMlc1PTFizszN M3u2c3NCVkeHUh?=
GI-1 NWKycW45T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTFzLki2NVUh|ryP M3;SRXNCVkeHUh?=
BB65-RCC Ml7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rYfGlEPTB;MUKuNFkyPiEQvF2= NWfsdYk{W0GQR1XS
NCI-H1651 M4XIUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrXNGJKSzVyPUGyMlI1PzhizszN NHK2T4lUSU6JRWK=
NCI-H1618 Mn[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkH1TWM2OD1zMj6zPVc3KM7:TR?= NXu1WoVKW0GQR1XS
NCI-H2081 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmWzTWM2OD1zMj62NVQyKM7:TR?= NGW0SHBUSU6JRWK=
GCIY MlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHmTWM2OD1zMj63NlE{KM7:TR?= NInQcJNUSU6JRWK=
NY M3W3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITDSmxKSzVyPUGzMlA3PDNizszN NFHIdlJUSU6JRWK=
PANC-03-27 NXLhXpFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1y3[GlEPTB;MUOuNFgxPyEQvF2= NVL5N3ppW0GQR1XS
BHY MlflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjs[nhKSzVyPUGzMlIyOjFizszN NHjROGdUSU6JRWK=
SK-OV-3 MnPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofPTWM2OD1zMz6zO|Y{KM7:TR?= MlzoV2FPT0WU
5637 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTF|Lke3OVkh|ryP MX;TRW5ITVJ?
LC-1F NEfue|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTydYh6UUN3ME2xOE4xOzV4IN88US=> NYjVU2xvW0GQR1XS
SNB75 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvYTWM2OD1zND6wN|g{KM7:TR?= MUPTRW5ITVJ?
CHP-212 Mk\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXnTWM2OD1zND6wOFY1KM7:TR?= MVXTRW5ITVJ?
HT-1376 M33jO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjiTWM2OD1zND6xNVI3KM7:TR?= NFTlV|NUSU6JRWK=
MONO-MAC-6 NF3IPXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLSeJNKSzVyPUG0MlE2ODJizszN MnXlV2FPT0WU
CA46 MlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPRXXFHUUN3ME2xOE4yQDJ5IN88US=> MnP3V2FPT0WU
SCC-15 MorjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zMbGlEPTB;MUSuOVU5OyEQvF2= NHnjcG1USU6JRWK=
ATN-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M136V2lEPTB;MUSuOlYzPyEQvF2= Mn;zV2FPT0WU
NCI-H2405 MoPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzJTWM2OD1zND64NVU4KM7:TR?= NYPadldFW0GQR1XS
NCI-H716 NXz3S5Y3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnKTWM2OD1zND64OFk{KM7:TR?= NIjaWXZUSU6JRWK=
SW620 NXnRUndHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvZfWZJUUN3ME2xOE46ODF2IN88US=> NGe1U3FUSU6JRWK=
NCI-H226 MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{ixPWlEPTB;MUSuPVA5PSEQvF2= Mn3JV2FPT0WU
SW962 NF3SRmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XLXWlEPTB;MUSuPVQ{OiEQvF2= MlfyV2FPT0WU
KYSE-150 NXTaNZRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2T5bGlEPTB;MUSuPVU2KM7:TR?= MkTGV2FPT0WU
OCUB-M MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkGyTWM2OD1zND65PFg{KM7:TR?= MUTTRW5ITVJ?
ES7 NUPHOmU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrzSZlbUUN3ME2xOU4xQTh2IN88US=> M3zMe3NCVkeHUh?=
SW1463 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fzbmlEPTB;MUWuOFIzOyEQvF2= MknNV2FPT0WU
CAKI-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTF3LkWzOFYh|ryP M3PJbnNCVkeHUh?=
MKN28 NIi4TWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\kTWM2OD1zNT61OFc6KM7:TR?= NV3vNGFYW0GQR1XS
SW13 MkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTF3Lk[xPEDPxE1? MoH5V2FPT0WU
A3-KAW MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTF3Lkm2PVch|ryP MX3TRW5ITVJ?
LU-65 NX;SNHNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDNT4NKSzVyPUG1Mlk4PjhizszN M1Ll[3NCVkeHUh?=
Calu-1 MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfDWodIUUN3ME2xOk4xOzZ6IN88US=> MYfTRW5ITVJ?
ST486 M4jaVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\CWolKSzVyPUG2MlA1OzFizszN NYrheGhoW0GQR1XS
BB30-HNC MlHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M161XGlEPTB;MU[uNVI1PiEQvF2= NX7VTmZ2W0GQR1XS
EGI-1 NW[3NYhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7LbFNTUUN3ME2xOk41PDZizszN NX3qRmpkW0GQR1XS
SH-4 NGrnVJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrZTlJNUUN3ME2xOk41PzNzIN88US=> MmDOV2FPT0WU
MN-60 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfKVJI4UUN3ME2xO{4zOjl5IN88US=> NUnNe5NRW0GQR1XS
MPP-89 M3HwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rHZmlEPTB;MUeuNlQ2QSEQvF2= NEPsXVFUSU6JRWK=
A2780 MlTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHzW3hKSzVyPUG3MlQyOzlizszN NWLifZBIW0GQR1XS
Daoy M4D1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzvdo1KSzVyPUG3MlQ3QTVizszN NWfzWZdrW0GQR1XS
NCI-H2126 NGPRXFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Po[2lEPTB;MUeuOFc4OSEQvF2= NWD1Oml{W0GQR1XS
NCI-H1563 NIXFS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XNbGlEPTB;MUeuOFkyPyEQvF2= NWqwVFZ7W0GQR1XS
8-MG-BA NXXmNIM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzzTWM2OD1zNz62OlQ5KM7:TR?= MXXTRW5ITVJ?
786-0 MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTF5LkizOVMh|ryP NH\CbG9USU6JRWK=
AM-38 MoLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NID2fpFKSzVyPUG3Mlk{ODZizszN Mmm0V2FPT0WU
COLO-824 M4fsXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3sb5RKSzVyPUG4MlQ1OzZizszN M4jFcnNCVkeHUh?=
SK-MEL-30 M2XxVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkWwTWM2OD1zOD61NFgzKM7:TR?= MnzJV2FPT0WU
CESS NGLUOnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWD6TllEUUN3ME2xPE44PjB7IN88US=> MlnnV2FPT0WU
BL-70 NWHFb|FHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTF6LkixOVYh|ryP NEnGSXNUSU6JRWK=
NCI-H2170 M{G1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITsVGhKSzVyPUG4MlkyPzlizszN M2LjTHNCVkeHUh?=
HT-3 NYW1c3JKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTF6Lkm4N{DPxE1? Ml7vV2FPT0WU
BOKU M3i1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTF7LkCzPFEh|ryP M2LvZ3NCVkeHUh?=
HPAF-II NGXOcYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrGPFRKSzVyPUG5MlMxOTVizszN MoTWV2FPT0WU
KGN NYX3[Y9{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nIdWlEPTB;MUmuOFc3PSEQvF2= NHL3Z2VUSU6JRWK=
MC-CAR NIHYbIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3WydWlEPTB;MUmuOlMyOyEQvF2= NF3LPWNUSU6JRWK=
BHT-101 NFjE[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfNNndKSzVyPUG5Mlc4PyEQvF2= M3Pme3NCVkeHUh?=
SW1783 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4qyfGlEPTB;MUmuO|gxPiEQvF2= NXLNUJJOW0GQR1XS
KP-N-YN MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTJyLkCyOlIh|ryP NWPNZY94W0GQR1XS
LU-165 NFS4c4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjWT|lKSzVyPUKwMlU2PzFizszN NU\GbIZ4W0GQR1XS
GOTO NF\B[nBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;BWFRKSzVyPUKwMlY1PTFizszN NGm0fZFUSU6JRWK=
EFM-19 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIX5U5lKSzVyPUKxMlA4OTZizszN MYnTRW5ITVJ?
CTV-1 NV61bmxnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTJzLkGwOVQh|ryP MV\TRW5ITVJ?
HEL MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPkTWM2OD1{MT60NlE3KM7:TR?= NVnMcWdHW0GQR1XS
SNU-C2B MnnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXFNotEUUN3ME2yNU41OjZizszN NWXuZXNlW0GQR1XS
ECC4 NFT5W|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPPZ4FKSzVyPUKxMlcxPyEQvF2= M13PO3NCVkeHUh?=
NEC8 MnXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnT3TWM2OD1{MT64N|Y5KM7:TR?= NXjqXmc1W0GQR1XS
KMOE-2 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Hze2lEPTB;MkGuPFkzOSEQvF2= NWnKdmZbW0GQR1XS
NCI-H524 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnscYFjUUN3ME2yNk4xQDB6IN88US=> NV\vNJVXW0GQR1XS
WSU-NHL Mn3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlX2TWM2OD1{Mj6xOVc4KM7:TR?= NESxeJJUSU6JRWK=
SF126 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnOTWdCUUN3ME2yNk4zPDZ7IN88US=> NEXRXnBUSU6JRWK=
HOP-92 NYfnUppNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjnRY1KSzVyPUKyMlMyPjdizszN MXPTRW5ITVJ?
CTB-1 NVTsdWJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXOeGdFUUN3ME2yNk41Pjd5IN88US=> NHPuOG9USU6JRWK=
KYSE-270 NFW0VY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTJ{LkmzOVch|ryP NHfGeVZUSU6JRWK=
SK-MEL-24 M{nXUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTJ|LkG4O{DPxE1? M1jueHNCVkeHUh?=
Calu-3 M2jlemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3qx[2lEPTB;MkOuNlEzQCEQvF2= NWP6RmhHW0GQR1XS
GAMG M4\zVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7OTFlKSzVyPUKzMlI{PjdizszN NHSzbG9USU6JRWK=
SW1573 NX;5eGoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjye|dKSzVyPUKzMlc1OTVizszN MlG1V2FPT0WU
MHH-NB-11 M2jkZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXLW4NKSzVyPUK0MlAyQTRizszN MXzTRW5ITVJ?
TK10 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEThcYZKSzVyPUK0MlUxOTNizszN NVfNd3VnW0GQR1XS
LB373-MEL-D MkDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTJ2Lk[wOlQh|ryP NInxPHVUSU6JRWK=
KALS-1 MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTJ2LkezNlch|ryP MXHTRW5ITVJ?
HUTU-80 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXTd|hKSzVyPUK1MlgxOzJizszN M13jbnNCVkeHUh?=
HuP-T3 NEizSXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTJ4LkG2O|Qh|ryP MULTRW5ITVJ?
OE19 M3TwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPDZWZGUUN3ME2yOk4zOTV|IN88US=> NWPCZ2gyW0GQR1XS
J82 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;hSIlKSzVyPUK2MlI1PzFizszN M4CzNnNCVkeHUh?=
DU-4475 NFTzc|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTJ4LkO4NVkh|ryP MUDTRW5ITVJ?
DMS-53 NITVTWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HINGlEPTB;Mk[uOVE{QCEQvF2= NGGzSpBUSU6JRWK=
COLO-741 M3;DW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;1UnpiUUN3ME2yOk45OzR2IN88US=> NYj5No5vW0GQR1XS
SW48 NInSfZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfOPGlKSzVyPUK2Mlg5OiEQvF2= NYHvNHhZW0GQR1XS
IGR-1 M1jsRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1naWGlEPTB;Mk[uPVM{PCEQvF2= MVzTRW5ITVJ?
639-V MmP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlS4TWM2OD1{Nz6wNlQ2KM7:TR?= MlHHV2FPT0WU
LK-2 MorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\HRZBKSzVyPUK3MlQyPDFizszN MWLTRW5ITVJ?
NCI-H2347 MlntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFj3dWtKSzVyPUK3Mlk3QTlizszN NUTRbml6W0GQR1XS
NCI-H2228 M{XNcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTJ6LkC5NFUh|ryP NWjLWYlzW0GQR1XS
LS-123 NEDN[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DCcmlEPTB;MkiuNVI3OiEQvF2= MU\TRW5ITVJ?
U031 M4W0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfoTWM2OD1{OD6yOVIh|ryP M1;1dnNCVkeHUh?=
NCI-H1792 NIDlbVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fTRWlEPTB;MkiuOFczOSEQvF2= NEji[nNUSU6JRWK=
NCI-H2087 NYTZbZRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfHT491UUN3ME2yPE44PTV{IN88US=> MnGxV2FPT0WU
NCI-H2342 Mom4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTJ7LkWyNFgh|ryP NHXHWGpUSU6JRWK=
SW626 M2XuXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrOZ2tKSzVyPUK5Mlc2PiEQvF2= MmXLV2FPT0WU
LB2518-MEL MlnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPSTWM2OD1{OT64NVUh|ryP MnXQV2FPT0WU
RXF393 NGPXdlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmT6TWM2OD1|MD6wPVUzKM7:TR?= NVrDfY5HW0GQR1XS
LC4-1 M4HIV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XZNmlEPTB;M{CuN|A6OiEQvF2= NYLBdItwW0GQR1XS
NCI-H1694 MnPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnOSlY3UUN3ME2zNE43PjJ2IN88US=> NGr1blFUSU6JRWK=
K5 M1fLfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\JTWM2OD1|MD65O|AzKM7:TR?= MWTTRW5ITVJ?
HDLM-2 MmGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnHbJBqUUN3ME2zNE46PzJ3IN88US=> MVzTRW5ITVJ?
BCPAP NEDF[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7mT3FLUUN3ME2zNU45Ozd7IN88US=> MnjoV2FPT0WU
BC-3 NEX4Z5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVf6fnFHUUN3ME2zNk4yPDB|IN88US=> NF34WHVUSU6JRWK=
LB996-RCC MmLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnmzTWM2OD1|Mj6yN|U5KM7:TR?= NH63O45USU6JRWK=
NCI-H2009 NGP1[2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDuTWM2OD1|Mj60PVgyKM7:TR?= MY\TRW5ITVJ?
HTC-C3 MkC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XrSGlEPTB;M{OuO|UyQSEQvF2= NXjNUFZFW0GQR1XS
LAMA-84 MnHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTN2LkS0NFch|ryP NHH0UmVUSU6JRWK=
CCRF-CEM M3LUZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:4ZlBKSzVyPUO0MlU4OTVizszN M2r1SXNCVkeHUh?=
AN3-CA MmXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17tN2lEPTB;M{WuNFU3QCEQvF2= NV\JepFHW0GQR1XS
NCI-H1734 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPsXpZKSzVyPUO1MlI2PjFizszN NVPyPI9JW0GQR1XS
Ca-Ski M32xc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnOZlBsUUN3ME2zOU41OTBzIN88US=> NHLvUmxUSU6JRWK=
U-266 NV3oZXNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTN3Lk[xNVQh|ryP M3;CNXNCVkeHUh?=
SBC-5 NFL0RWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTN3Lke3PFEh|ryP NWnIO|BNW0GQR1XS
GT3TKB MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LOXmlEPTB;M{euNVE2KM7:TR?= MnTsV2FPT0WU
MDA-MB-175-VII Ml;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LkZWlEPTB;M{euNlI1QCEQvF2= NX7ndXRRW0GQR1XS
PFSK-1 NVjXOIlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjaboJKSzVyPUO3MlI1OzVizszN NFHzZZRUSU6JRWK=
IMR-5 M4Lvemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzmTWM2OD1|Nz6yOFg4KM7:TR?= NWH6foN2W0GQR1XS
Daudi NH7FPHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfJTWM2OD1|Nz6zOVk4KM7:TR?= M1HIeHNCVkeHUh?=
A498 M{jJe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVf6T5dYUUN3ME2zO{44OjF6IN88US=> MljTV2FPT0WU
SCC-4 NHHQfIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTVTWM2OD1|Nz63PFQ{KM7:TR?= MUDTRW5ITVJ?
COLO-680N NXz6No5wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfTTWM2OD1|OD6yPFg2KM7:TR?= M3TiPXNCVkeHUh?=
SK-MES-1 MmXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnv4TWM2OD1|OD6zNlE2KM7:TR?= M4nLVXNCVkeHUh?=
SR NWDRXYFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXS1TYh3UUN3ME2zPE42PDl3IN88US=> M1HaZ3NCVkeHUh?=
LNCaP-Clone-FGC NGrle45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\KTWM2OD1|OD61OlM4KM7:TR?= M4Lw[HNCVkeHUh?=
SK-HEP-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGezWGpKSzVyPUO4Mlc5OjJizszN MYLTRW5ITVJ?
BPH-1 M1PpdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkP4TWM2OD1|OD64N|I6KM7:TR?= MXrTRW5ITVJ?
NCI-H1755 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrxUYJkUUN3ME2zPU42QDF5IN88US=> MmnlV2FPT0WU
LXF-289 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnESGVwUUN3ME2zPU45ODh2IN88US=> MmfwV2FPT0WU
SW1088 NHT6N5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTRyLkKxNFch|ryP MUDTRW5ITVJ?
MOLT-4 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTRyLkK5NFEh|ryP NUjoS2hGW0GQR1XS
AsPC-1 NWHueXBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrJTWM2OD12MD60OVg{KM7:TR?= MkXyV2FPT0WU
HOP-62 M3XvTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3oclg3UUN3ME20NE43PTZ6IN88US=> MnL5V2FPT0WU
A172 NWmzXo1vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TxTWlEPTB;NECuPFUyOSEQvF2= MWfTRW5ITVJ?
SN12C NVnpN3pjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jyZ2lEPTB;NECuPVM5PSEQvF2= NX7jV3RvW0GQR1XS
MDA-MB-231 NILwTpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TTeGlEPTB;NECuPVg6QCEQvF2= M1fFfHNCVkeHUh?=
RPMI-2650 Mk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Tl[2lEPTB;NEGuNVU6OyEQvF2= M3vVcHNCVkeHUh?=
KYSE-140 MnvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTRzLkixNlMh|ryP MVjTRW5ITVJ?
KINGS-1 M{fsWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NECxOJNKSzVyPUSyMlQ3QTdizszN MUPTRW5ITVJ?
HSC-3 NVPLcI1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPFcVJKSzVyPUSyMlY3PjFizszN NYPLZXhYW0GQR1XS
PC-14 M{PI[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXBTllKSzVyPUSzMlE5QDJizszN MX\TRW5ITVJ?
COR-L105 M{m2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HVfmlEPTB;NEOuOlUxOiEQvF2= NUC2fIdmW0GQR1XS
BE-13 M4D3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXmU5NMUUN3ME20OE4zOzdzIN88US=> NGPNRmRUSU6JRWK=
NCI-H661 MkXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7z[mYzUUN3ME20OE4zQTV6IN88US=> MYXTRW5ITVJ?
IST-MEL1 MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHYTWM2OD12ND6zOVk6KM7:TR?= M1LPfXNCVkeHUh?=
HCC1806 Mk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGCzc2JKSzVyPUS0MlU5PzNizszN M1HxeHNCVkeHUh?=
COLO-800 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvReHpCUUN3ME20OE45PDV|IN88US=> Mnf5V2FPT0WU
IST-SL2 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fNdGlEPTB;NEWuNVI1PyEQvF2= NYDIZWw{W0GQR1XS
8305C M{HGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTR3LkOwPUDPxE1? NF2yZYlUSU6JRWK=
UACC-62 NVnXe29xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2frd2lEPTB;NE[uNlg4PSEQvF2= NIPHVYdUSU6JRWK=
COR-L23 NFjSSlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHHbVhKSzVyPUS3MlE6QSEQvF2= MVLTRW5ITVJ?
EFE-184 NV\3Z5RUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoGyTWM2OD12Nz6zPFgh|ryP Moi0V2FPT0WU
DMS-114 M{Tsb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnTTWM2OD12Nz60NVQ6KM7:TR?= M3nBdnNCVkeHUh?=
KYSE-520 NFTneVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4H2ZWlEPTB;NEiuOVMyPSEQvF2= NUHUTos5W0GQR1XS
SNG-M MmTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTnNmg6UUN3ME20PU41OzRizszN M3TGdnNCVkeHUh?=
A2058 MmGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTR7LkS4PFUh|ryP NELTV5ZUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]

Protocol

Kinase Assay:[1]
+ Expand

Protein kinase biochemical assays:

Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.
Cell Research:[1]
+ Expand
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3 days
  • Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
  • Formulation: 25 mM tartaric acid
  • Dosages: 25 mg / kg and 75 mg / kg
  • Administration: Orally administrated at once-daily oral dose for 14 days
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 84 mg/mL (199.29 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
In vivo 30% PEG 400+0.5% Tween 80+5% Propylene glycol 30mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 421.49
Formula

C26H23N5O

CAS No. 867160-71-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development, Inc.|Astellas Pharma Inc April 2014 Phase 2
NCT02546544 Active, not recruiting Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01567384 Withdrawn Cancer|Neoplasms|Tumors Emory University|OSI Pharmaceuticals May 2012 Phase 1
NCT01560260 Completed Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma National Cancer Institute (NCI) March 2012 Phase 2
NCT01533246 Completed Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer National Cancer Institute (NCI) February 2012 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Tags: buy Linsitinib (OSI-906) | Linsitinib (OSI-906) supplier | purchase Linsitinib (OSI-906) | Linsitinib (OSI-906) cost | Linsitinib (OSI-906) manufacturer | order Linsitinib (OSI-906) | Linsitinib (OSI-906) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID